Thymosin Alpha-1 Explained: Mechanism, Zadaxin Status, and the 2026 FDA Controversy

Thymosin Alpha-1longevity

Synthetic 28-amino-acid immunomodulatory peptide. Approved as Zadaxin in 35+ countries for chronic hepatitis B and C. Studied in 30+ trials across 11,000+ subjects for immune modulation via TLR2/9 dendritic cell signaling.

What is Thymosin Alpha-1?

Thymosin Alpha-1 (TA1, also known by the brand name Zadaxin and the INN Thymalfasin) is a synthetic peptide of 28 amino acids. Allan Goldstein and his team at the Albert Einstein College of Medicine isolated the substance from bovine thymus in 1972 as part of the broader "Thymosin Fraction V". The N-terminally acetylated structure was later made reproducible 1:1 through solid-phase synthesis.

In the body, TA1 is generated by proteolytic cleavage of prothymosin alpha in the thymus gland and circulates at low picomolar concentrations. It therefore belongs to the class of endogenous immunomodulators, not to the hormones in the classical sense.

How Thymosin Alpha-1 works

TA1 does not act as a cytokine or growth factor but as a receptor agonist on the toll-like receptors TLR2 and TLR9, which are expressed primarily on dendritic cells. This activation triggers a characteristic dual signature:

• Pro-inflammatory arm: Th1 activation, increased CD4+ helper and CD8+ cytotoxic T-cell populations, enhanced pathogen defence
• Tolerogenic arm: IDO-mediated Treg generation, balancing the pro-inflammatory shift and preventing autoimmune escalation

In the thymectomised animal model, TA1 restores T-cell function. Differentiation of precursor cells is accelerated, and lymphocyte counts depleted by chronic infection or ageing are rebalanced.

This dual signature mechanistically sets TA1 apart from classical immunotherapies such as interferon alpha or interleukin-2, which only push in one direction.

Clinical evidence: 30+ RCTs, 11,000+ subjects

A 2024 Frontiers in Medicine review documents more than 30 randomised controlled trials of TA1 with a combined enrolment of over 11,000 subjects. The main indications:

Chronic hepatitis B TA1 has been investigated in several phase-3 trials as monotherapy and in combination with interferon alpha. The approved standard dose is 1.6 mg subcutaneously twice weekly for 6 to 12 months. Virological response rates in combination therapy were consistently superior to interferon monotherapy.

Chronic hepatitis C A similar picture to HBV, primarily as an adjuvant to classical antiviral regimens before the arrival of the direct-acting antivirals.

Sepsis and critical illness Several Chinese multi-centre trials evaluated TA1 in severe sepsis, with signals of reduced 28-day mortality and restoration of lymphocyte counts.

COVID-19 Hospitals in Wuhan and Beijing used TA1 under protocol for severe COVID-19 cases. A 2020 study reported reduced ICU admission rates and 28-day mortality, especially in older patients.

Why 35 countries yes, FDA no

Zadaxin (SciClone Pharmaceuticals) has been approved since the 1990s as a prescription drug in more than 35 countries. The most important markets:

• Italy (chronic hepatitis B and C, primary approval)
• Mexico, Brazil, Argentina
• China, Singapore, the Philippines
• Egypt, Saudi Arabia

EU-wide EMA approval was never actively pursued, because Italy as a national approval was considered sufficient market entry and a parallel EMA submission would have made the patent status vulnerable.

In the United States, the FDA has never approved Thymosin Alpha-1. The reasons are well documented:

1. Trial geography: Most pivotal trials took place in Italy and Asia, not in US centres
2. Endpoint definition: HBV endpoints differ between the FDA and EMA, and a re-analysis would be costly
3. Patent lifecycle: SciClone focused on markets where it was already approved rather than chasing an expensive FDA submission
4. Compounding market: Until early 2024, TA1 sat in FDA category 2 (compounding allowed), which reduced pressure for formal approval

Thymosin Alpha-1 vs Thymalin

Because of the similar names, TA1 and Thymalin are routinely confused in the market. They are chemically and mechanistically entirely different.

Property	Thymosin Alpha-1	Thymalin
Structure	28-amino-acid peptide, defined sequence	Peptide complex of several small fragments, primarily the Glu-Trp dipeptide
Origin	Synthetic, based on the bovine Goldstein isolate	Russian, Khavinson school, originally extracted from calf thymus
Mechanism of action	Direct TLR2/TLR9 agonism, accelerated T-cell maturation	Bioregulator concept: epigenetic regulation at the organ level
Clinical approval	Zadaxin in 35+ countries for hepatitis	Russia for immune senescence and oncology adjuvant use
Half-life	Short (~2h), but repeat dosing is well established	Long duration of action through epigenetic effects
Standard dose	1.6 mg subcutaneously, 2x weekly	5-10 mg daily, 10-20 day course, 1-2x per year

Both peptides are investigated in research as complementary approaches to modulating thymus-mediated immune function. Stack studies are rare but published.

COVID-19 and the turning point

The COVID-19 pandemic unexpectedly thrust TA1 into the spotlight. From February 2020 onward, Chinese hospitals documented protocol-driven use in severe cases, with outcome data published in Frontiers in Pharmacology (PMID 33347925).

A pilot trial in haemodialysis patients on the prevention of COVID-19 infection and morbidity (Thymalfasin/TA1, 2021) showed trends toward reduced hospitalisation. The studies are statistically underpowered for firm conclusions but consistent with the TLR2/TLR9 mechanism.

Western practice has not adopted TA1 in COVID-19 guidelines, primarily because the studies were not submitted in EMA/FDA format.

Research applications in 2026

Current research fields involving TA1:

• Immune senescence: restoration of thymic output in older subjects
• Oncology adjuvant: combination with checkpoint inhibitors in phase-2 trials (China)
• Chronic infections: hepatitis B cure strategies, latent viral reservoirs
• Vaccine adjuvant: boosts antibody response to influenza and HBV vaccines in the very elderly

The standard dose in non-oncology research protocols is 1.6 mg subcutaneously twice weekly for 4 to 12 weeks, matching the established Zadaxin regimen.

Quality and sourcing

TA1 is supplied as a lyophilised powder in 5 mg to 10 mg vials. Key quality criteria:

• Purity: at least 98% by HPLC, ideally with mass spectrometry confirmation
• Sequence verification: N-terminal acetylation must be demonstrable, a common point of adulteration
• Endotoxin: critical for subcutaneous use, should sit below pharmacopoeial limits
• Third-party testing: Janoshik reports or equivalent per batch

Thymosin Alpha-1longevity

Synthetic 28-amino-acid immunomodulatory peptide. Approved as Zadaxin in 35+ countries for chronic hepatitis B and C. Studied in 30+ trials across 11,000+ subjects for immune modulation via TLR2/9 dendritic cell signaling.

For reconstitution, bacteriostatic or sterile water is used, typically 1-2 mL per 5 mg vial.

Bacteriostatic Wateraccessories

USP-grade sterile water with 0.9% benzyl alcohol - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.

Frequently asked questions